Atossa Therapeutics (ATOS)
2.52
-0.01 (0.40%)
Upcoming Events
Latest Headlines
Atossa Genetics (ATOS) Tops Q2 EPS by 10c
August 7, 2026 8:59 AM - StreetInsider
Form 8-K ATOSSA THERAPEUTICS, For: Aug 07
August 7, 2026 8:45 AM - SEC Filing
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 7, 2026 8:45 AM - PR NewsWire
Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30
August 7, 2026 8:31 AM - SEC Filing
Atossa preclinical study on endoxifen compounds published in npj
July 28, 2026 8:30 AM - StreetInsider
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
July 28, 2026 8:30 AM - PR NewsWire
Atos achieves CMMC 2.0 Level 2 certification, strengthening readiness for mission-critical and complex defense programs
July 23, 2026 12:59 PM - Globe NewsWire
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
July 21, 2026 8:30 AM - PR NewsWire
Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy
July 7, 2026 7:50 AM - StreetInsider
Atossa Therapeutics closes $4.5 million registered direct offering
June 12, 2026 5:31 PM - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
June 12, 2026 5:31 PM - PR NewsWire
Form 424B5 ATOSSA THERAPEUTICS,
June 12, 2026 9:17 AM - SEC Filing
Atossa Therapeutics raises $4.5 million in registered direct offering
June 11, 2026 8:01 AM - StreetInsider
Form 8-K ATOSSA THERAPEUTICS, For: Jun 10
June 11, 2026 8:00 AM - SEC Filing
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
June 11, 2026 8:00 AM - PR NewsWire
Full Article List
